ClinicalTrials.gg
RecruitingNCT07113223DECISIONUpdated Nov 4, 2026

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

An interventional study of Willem™ platform ECG assessment in Heart Failure and Cardiovascular Risk Factors, sponsored by Idoven 1903 S.L.. Recruiting at 5 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Idoven 1903 S.L. · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,968
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Planned enrollment
39th of 263
1,968 · median 294
Started
2025
with 30 others
No phase
119 of 342
34 open now
Primary completion
2027-03
later than 40 of 98 live
Registered
312th of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 39th largest by planned enrollment of the 263 interventional ones that give a count, is one of 31 that started in 2025, is one of 119 with no phase, reaches primary completion later than 40 of the 98 other live ones, and was the 312th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk.

This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.

Read the detailed description

Heart failure (HF) is a prevalent and underdiagnosed condition with high morbidity and mortality. Up to 50% of HF cases remain undetected, often due to subtle or absent symptoms in early stages. Early diagnosis is critical to improving outcomes, reducing hospitalizations, and alleviating healthcare costs. While ECGs are a cornerstone in HF diagnosis, their interpretation in primary care can be challenging, leading to diagnostic delays.

Artificial intelligence (AI) has emerged as a promising tool to support clinicians by enhancing ECG interpretation. In this regard, the DECISION trial evaluates the Willem™ platform, an AI-powered decision-support system, to improve HF detection. Willem™ uses a proprietary database to analyze ECGs, identifying over 80 cardiac patterns with high accuracy.

This study hypothesizes that AI-assisted ECG improves HF detection compared to standard ECG interpretation. Therefore, the main goal of the DECISION trial is to assess the diagnostic performance of AI-assisted ECG in detecting structural and functional cardiac abnormalities indicative of HF.

This multicenter, randomized trial includes primary care centers (PCCs) in Spain and Sweden, randomized into two groups: an intervention group using AI-assisted ECG and a control group using standard ECG. AI outputs will be available for physicians in the intervention group as supplementary information during decision making.

Primary outcomes focus on the accuracy of HF detection confirmed by transthoracic echocardiograms (TTE). Secondary outcomes include healthcare resource utilization, clinical outcomes, and physician satisfaction. The results will inform whether AI can be integrated into primary care workflows to optimize HF diagnosis and management.

03

Conditions studied

  • Heart Failure
  • Cardiovascular Risk Factors

Browse trials for

Keywords

  • Heart Failure
  • Artificial Intelligence
  • Electrocardiogram (ECG)
  • Primary Care
  • Diagnostic Tools
  • Cardiology
  • Electrocardiography
  • Risk Stratification
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Suspected HF (Group S):

    • Able to understand and accept the study constraints and to provide (either themselves or a legal representative).
    • Age over 65 years (i.e., 65 included).
    • Presence of symptoms and/or signs typical of Heart Failure (defined by the European Society of Cardiology, ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.
  • Patients at Risk of Heart Failure due to the presence of cardiovascular (Group R):

    • Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).
    • Age over 65 years (i.e., 65 included).
    • Absence of symptoms and/or signs typical of Heart Failure (defined by the ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.
    • Presence of at least 1 ACC/AHA Heart Failure risk factor, including hypertension, cardiovascular disease (atrial fibrillation, coronary heart disease or stroke), diabetes, obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or family history of cardiomyopathy that requires an test for any reason in a primary care center or with an indication of a regular health examination where an ECG is included.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness or inability to sign the written .
  • Previous Heart Failure diagnosis.
  • Unavailability or suboptimal quality .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,968 participants (estimated)

Study arms

  • Experimental
    Experimental

    AI-assisted ECG analysis via the Willem™ platform

    Device: Willem™ platform ECG assessment

  • No intervention
    Comparator

    Standard ECG assessment

Interventions

  • DeviceWillem™ platform ECG assessment

    AI-assisted ECG analysis via the Willem™ platform

06

What researchers measure

Primary outcomes

  1. Device performance in patients with suspected Heart Failure

    To compare the diagnostic performance of clinicians using a decision-aid system based on AI-assisted ECG vs. standard ECG in patients with suspected Heart Failure (symptoms and/or signs of Heart Failure) in the primary care setting analyzing the frequency of patients without cardiac pattern alterations in the ECG, ending up with diagnosis of absence of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 7 days after screening with the cardiology service.

    Time frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)

Secondary outcomes

  1. Device performance in patients at cardiovascular risk but without Heart Failure symptoms

    To compare the diagnostic performance of clinicians using a decision-aid system based on AI-assisted ECG vs. standard ECG in patients at risk but without Heart Failure symptoms in the primary care setting analyzing the frequency of patients with cardiac pattern alterations in the ECG, ending up with a diagnosis of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 7 days after screening with the cardiology service.

    Time frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)

  2. Device performance at 6 months after ECG

    To compare the clinical performance of a decision-aid system based on AI-assisted ECG vs standard ECG, in patients with symptoms and patients at risk of Heart Failure in the primary care setting analyzing the frequency of patients with cardiac pattern alterations in the ECG, ending up with diagnosis of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 6 months after screening with the cardiology service.

    Time frame: Six months after the ECG was performed

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified Individual Participant Data (IPD) that underlies the results reported in the publication will be shared after publications of primary results upon request of investigators whose proposed research has received EC/IRB approval and after data use agreement.

Supporting information: Study protocol

Time frame: From the time of publication and for 5 years thereafter.

Access criteria: Upon request of investigators whose proposed research has received EC/IRB approval and after data use agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 20 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Mar 2027 and completion Mar 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 8, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Mar 2027was Sep 2026
CompletionEst.
May 2027was Mar 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Mar 2027
Nov 4, 2026
Study completion
Mar 2027→May 2027
Nov 4, 2026
Sponsor
Collaborators added: Hospital Universitario 12 de Octubre; collaborators removed: Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Sep 2026→Mar 2027
    Study completion Mar 2027→May 2027
    Sponsor Collaborators added: Hospital Universitario 12 de Octubre; collaborators removed: Fundación para la Investigación Biomédica del Hospital 12 de Octubre

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07113223
Lead sponsor
Idoven 1903 S.L.
Collaborators
Hospital Universitario 12 de Octubre, Fundación para la Investigación Biomédica del Hospital Gregorio Maranon, Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria de la Comunidad de Madrid (FIIBAP), Instituto de Investigación Marqués de Valdecilla, Karolinska Institutet, Region Stockholm, AstraZeneca, Servicio Madrileno De Salud (SERMAS)
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Jul 23, 2025
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Juan Francisco Delgado Jiménez, MD, PhD
Contact
juan.delgado@salud.madrid.org
+34917792640

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion